Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib in ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
NCT06282874Phase 4Active, not recruiting
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Aug 2024
- Primary completion
- Apr 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lorlatinib in non-small cell lung cancer (NSCLC), brain metastases and leptomeningeal metastasis (LM), sponsored by Guangdong Association of Clinical Trials. Primary endpoint: Intracranial Objective Response Rate up to 18 months. Started Aug 2024; status: active, not recruiting.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastasesleptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT06282874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06282874.